AFT Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • AFT Pharmaceuticals's estimated annual revenue is currently $24.3M per year.(i)
  • AFT Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • AFT Pharmaceuticals has 121 Employees.(i)
  • AFT Pharmaceuticals grew their employee count by 5% last year.

AFT Pharmaceuticals's People

NameTitleEmail/Phone
1
Global Category ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.3M1215%N/AN/A
#2
$18.9M94-3%N/AN/A
#3
$62.7M3124%N/AN/A
#4
$95.3M474N/AN/AN/A
#5
$148.9M7414%N/AN/A
#6
$14.7M730%N/AN/A
Add Company

What Is AFT Pharmaceuticals?

Back in 1997, husband and wife team Hartley and Marree Atkinson hit the road selling products direct to pharmacies. AFT Pharmaceuticals was formed with a big dream in mind. In Australasia, our product line now extends to over 130 prescription and non-prescription products. We have offices in Singapore, Kuala Lumpur, Sydney and Auckland (our HQ). We export or license our products to over 109 countries. Plus our Orphan Drugs Foundation provides access to lower cost pharmaceuticals for people with rare diseases within South East Asia and the Pacific. This success has been built on research and development. R&D is more than corporate speak for us. It’s at the heart of what we do, whether it’s developing new products, or improving existing existing ones. It’s also due to the fact that we are close to the market. Because we sell our own products we are constantly looking for changes in health needs and how we can fill gaps that emerge. Our ideas, our researchers, our specialist drug development programmes, and the international experts we partner with have allowed us to grow year on year. It’s how we’ve managed to forge a place on the world stage in the extremely competitive pharmaceutical industry. We're proud of our past achievements. We’re ambitious for the future.

keywords:N/A

N/A

Total Funding

121

Number of Employees

$24.3M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AFT Pharmaceuticals News

2022-04-19 - Dry Eye Syndrome Treatment Market Size And Forecast ...

Ltd., AFT Pharmaceuticals, Novaliq GmBH, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd.and others.

2022-04-06 - AFT Pharmaceuticals (ASX:AFP) wins in High Court comparative advertising judgment

The Australian High Court sides with AFT Pharmaceuticals (AFP) in a dispute over advertising comparing its product, Maxigesic,...

2021-11-18 - AFT Pharmaceuticals : 211118 AFT 1H FY22 Market ReleaseOpens in a new Window

Market release 18 November 2021 UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2021 AFT reaffirms guidance and progresses growth plan HIGHLIGHTS* Revenue rises 14% to $55.5 million from $48.8 million despite multiple COVID-19 challenges Growth led by International (+74%), Ne ...

2021-11-17 - AFT Pharmaceuticals : 211118 AFT 1H FY22 Market Release

For personal use only Market release 18 November 2021 UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2021 AFT reaffirms guidance and progresses growth plan HIGHLIGHTS* Revenue rises 14% to $55.5 million from $48.8 million despite multiple COVID-19 challenges Growth led by I ...

2021-07-13 - GENERAL: AFT: Maxigesic® Oral Liquid gets first regulatory approvalOpens in a new Window

14 July 2021 Maxigesic® Oral Liquid gets first regulatory approval Maxigesic Oral Liquid - a non-opioid analgesic developed for children - achieves first approval in Europe to set up the first global launch and a pathway for further registrations and launches. AFT Pharmaceuticals (NZX; AFT, A ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22M12223%N/A
#2
$17.1M122-27%$135M
#3
$19.7M12315%N/A
#4
$26M124-1%N/A
#5
$36M12439%N/A